Openbookopenbook
Equity
Genfit SA Sponsored ADR(GNFTY)
USD --+0.00%
Reward36Moderate
Risk46Moderate
📊75%Data
Thin -86% profit margin · Revenue down 42% YoY
GNFTY
+0.0 · +0.00%
USD · NASDAQ
Genfit SA Sponsored ADR | Healthcare
Earnings Deterioration
Market Cap:511.44M
ℹ️
Reward Rating
36
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
46
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on GNFTY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: €8.42.

What is Genfit SA Sponsored ADR?

, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

GNFTY · Verdict

Limited reward · moderate risk

GNFTY has limited near-term tailwinds — growth and valuation weigh on the model output.

Based on 88% data coverage

GNFTY · Verdict

What’s working & what to watch

Watchouts 2

  • Growth20/100

    Rev -5.8% CAGR · earnings -71.8%

  • Valuation36/100

    P/E 344.8×

Model-based scoring. For information only — not financial advice.

What is Genfit SA Sponsored ADR?

, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 511.44M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)

The scoring profile indicates weak reward characteristics across most factors, including profitability and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap511.44M
P/E RatioN/A
Dividend YieldN/A
52 Week High10.2
52 Week Low2.55
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding50M
No. of Employees188
IndustryBiotechnology
ExchangeNASDAQ
Beta0.975
CurrencyUSD · Reports in EUR
Websitewww.genfit.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.